This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05083/identifier/pubchem-substance/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05083/identifier/drugbank/
n12http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB05083/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB05083/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05083
rdf:type
n3:Drug
n3:description
TMC278 is an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) under development. TMC278 is a diarylpyrimidine derivative, a new series of NNRTIs which show high intrinsic activity against both wild-type HIV-1 and against HIV strains harboring resistance inducing mutations.
n3:generalReferences
# Boone LR: Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16499282
n3:group
investigational
n3:halfLife
38 hours
n3:indication
Investigated for use/treatment in HIV infection.
owl:sameAs
n12:DB05083
dcterms:title
TMC278
adms:identifier
n6:DB05083 n7:6451164 n8:4953643 n9:10560392
n3:IUPAC-Name
n4:271B6348-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B634E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B634D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B634A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B634B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B634C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6346-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6344-363D-11E5-9242-09173F13E4C5 n4:271B6347-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6345-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B6354-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6355-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B634F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6350-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6352-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6351-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6353-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
500287-72-9
n3:Bioavailability
n4:271B635A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B635C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B635D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6359-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6358-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B635B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6349-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6356-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6357-363D-11E5-9242-09173F13E4C5